Stocks Overview

LAST PRICE
6.3500
TODAY'S CHANGE (%)
Trending Down-0.2200 (-3.3486%)

Bid / Lots
6.2500/ 1
Ask / Lots
6.5500/ 54
Open / Previous Close
6.5100 / 6.5700
Day Range
Low 6.2300
High 6.5600
52 Week Range
Low 1.0600
High 11.8800
Volume
2,458,060
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 6.57
Time	Volume	CCCC
09:32 ET	125217	6.432
09:34 ET	2161	6.56
09:36 ET	309	6.46
09:38 ET	1300	6.47
09:39 ET	3059	6.4774
09:41 ET	3140	6.445
09:43 ET	2032	6.45
09:45 ET	2379	6.395
09:48 ET	10780	6.348
09:50 ET	311	6.3577
09:52 ET	4572	6.35
09:54 ET	3982	6.41
09:56 ET	10700	6.42
09:57 ET	2813	6.4
09:59 ET	1202	6.39
10:01 ET	1500	6.425
10:03 ET	1125	6.44
10:06 ET	1632	6.4277
10:08 ET	1000	6.38
10:10 ET	1389	6.38
10:12 ET	786	6.38
10:14 ET	882	6.38
10:15 ET	1493	6.38
10:17 ET	1500	6.38
10:19 ET	1100	6.385
10:21 ET	456	6.385
10:24 ET	1052	6.39
10:26 ET	4794	6.3984
10:28 ET	828	6.42
10:30 ET	300	6.42
10:32 ET	1096	6.41
10:33 ET	1566	6.41
10:35 ET	300	6.4
10:37 ET	206	6.395
10:39 ET	200	6.42
10:42 ET	100	6.43
10:44 ET	200	6.43
10:46 ET	480	6.4277
10:50 ET	340	6.4
10:51 ET	843	6.42
10:53 ET	100	6.395
10:55 ET	756	6.39
10:57 ET	304	6.39
11:00 ET	600	6.37
11:02 ET	665	6.37
11:04 ET	11307	6.35
11:06 ET	4233	6.36
11:08 ET	618	6.36
11:09 ET	300	6.35
11:11 ET	950	6.36
11:13 ET	4017	6.3478
11:15 ET	1131	6.36
11:18 ET	598	6.34
11:20 ET	300	6.34
11:22 ET	1108	6.3577
11:26 ET	100	6.35
11:27 ET	3200	6.35
11:29 ET	26589	6.275
11:31 ET	1568	6.275
11:33 ET	2164	6.25
11:36 ET	5717	6.32
11:38 ET	491	6.34
11:40 ET	1250	6.35
11:42 ET	5462	6.34
11:44 ET	536	6.33
11:45 ET	413	6.3677
11:47 ET	350	6.355
11:49 ET	700	6.3516
11:51 ET	680	6.34
11:54 ET	899	6.335
11:56 ET	250	6.325
11:58 ET	605	6.35
12:00 ET	573	6.35
12:03 ET	300	6.35
12:09 ET	100	6.35
12:12 ET	500	6.34
12:14 ET	3281	6.34
12:16 ET	1415	6.36
12:20 ET	200	6.36
12:23 ET	100	6.36
12:27 ET	100	6.365
12:30 ET	1310	6.3477
12:32 ET	1140	6.35
12:34 ET	488	6.35
12:36 ET	250	6.3483
12:38 ET	860	6.33
12:41 ET	200	6.33
12:45 ET	105	6.33
12:50 ET	515	6.33
12:52 ET	100	6.35
12:54 ET	1701	6.37
12:56 ET	200	6.37
12:57 ET	364	6.3623
12:59 ET	100	6.3737
01:01 ET	200	6.38
01:03 ET	200	6.37
01:06 ET	697	6.38
01:08 ET	662	6.39
01:10 ET	1033	6.39
01:12 ET	5801	6.41
01:14 ET	1200	6.395
01:15 ET	1737	6.3823
01:17 ET	600	6.39
01:19 ET	823	6.39
01:21 ET	1117	6.4
01:24 ET	1818	6.39
01:26 ET	5823	6.38
01:28 ET	568	6.36
01:30 ET	2183	6.32
01:32 ET	2557	6.32
01:33 ET	800	6.33
01:35 ET	1045	6.35
01:37 ET	672	6.34
01:39 ET	1600	6.3499
01:42 ET	768	6.33
01:44 ET	900	6.35
01:46 ET	600	6.33
01:48 ET	1000	6.33
01:50 ET	324	6.33
01:51 ET	733	6.32
01:53 ET	400	6.32
01:55 ET	3545	6.33
01:57 ET	659	6.34
02:00 ET	723	6.3
02:02 ET	1209	6.31
02:04 ET	1300	6.29
02:06 ET	2170	6.29
02:08 ET	1015	6.29
02:09 ET	1593	6.31
02:11 ET	700	6.3
02:13 ET	858	6.31
02:15 ET	600	6.3
02:18 ET	4096	6.305
02:20 ET	840	6.3
02:22 ET	500	6.3
02:24 ET	5966	6.3
02:26 ET	1541	6.291
02:27 ET	700	6.28
02:29 ET	700	6.28
02:31 ET	1758	6.285
02:33 ET	6040	6.315
02:36 ET	1096	6.3
02:38 ET	200	6.3
02:40 ET	506	6.31
02:42 ET	1723	6.35
02:44 ET	363	6.35
02:45 ET	1776	6.39
02:47 ET	4000	6.385
02:49 ET	3259	6.39
02:51 ET	100	6.39
02:54 ET	700	6.39
02:56 ET	1300	6.38
02:58 ET	1700	6.36
03:00 ET	1700	6.33
03:02 ET	2300	6.33
03:03 ET	17109	6.41
03:05 ET	4598	6.42
03:07 ET	2015	6.4
03:09 ET	4009	6.38
03:12 ET	2705	6.3792
03:14 ET	2400	6.39
03:16 ET	1803	6.39
03:18 ET	1317	6.38
03:20 ET	1212	6.36
03:21 ET	2000	6.34
03:23 ET	5094	6.355
03:25 ET	3794	6.33
03:27 ET	2810	6.32
03:30 ET	2015	6.35
03:32 ET	700	6.35
03:34 ET	1708	6.34
03:36 ET	2928	6.34
03:38 ET	6321	6.35
03:39 ET	5297	6.345
03:41 ET	3227	6.33
03:43 ET	3460	6.33
03:45 ET	2494	6.33
03:48 ET	52933	6.34
03:50 ET	7853	6.32
03:52 ET	34189	6.305
03:54 ET	50715	6.35
03:56 ET	106981	6.35
03:57 ET	100691	6.35
03:59 ET	1343133	6.35

Data delayed at least 15 minutes.

Sep 13, 2024
- C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024, from 10:00AM ET on Friday Sep 13, 2024 by Dow Jones
  10:00AM ET on Friday Sep 13, 2024 by Dow Jones
Sep 10, 2024
- C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen, from 7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
  7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 8, 2024
- C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024, from 6:05PM ET on Sunday Sep 08, 2024 by Dow Jones
  6:05PM ET on Sunday Sep 08, 2024 by Dow Jones
Sep 3, 2024
- Press Release: C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors, from 7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
  7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
- C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors, from 7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
  7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesCCCC C4 Therapeutics Inc	455.5M	-3.3x	---
United StatesACIU AC Immune SA	364.4M	-4.9x	---
United StatesTSHA Taysha Gene Therapies Inc	448.8M	-2.4x	---
United StatesVERV Verve Therapeutics Inc	455.3M	-2.0x	---
United StatesITOS Iteos Therapeutics Inc	409.8M	-3.8x	---
United StatesPRTC PureTech Health PLC	462.4M	-6.5x	---
As of 2024-09-20

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.

Contact Information

Headquarters: 490 Arsenal Way, Suite 120WATERTOWN, MA, United States 02472
Phone: 617-231-0700
Fax: 302-655-5049

Executives

Independent Chairman of the Board: Ronald Cooper
President, Chief Executive Officer, Director: Andrew Hirsch
Chief Financial Officer, Treasurer: Kendra Adams
Chief People Officer: Kelly Schick
Chief Scientific Officer: Stewart Fisher

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$455.5M
Revenue (TTM)	$29.4M
Shares Outstanding	69.3M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	3.06
EPS	$-1.90
Book Value	$4.07
P/E Ratio	-3.3x
Price/Sales (TTM)	15.5
Price/Cash Flow (TTM)	---
Operating Margin	-406.82%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

C4 Therapeutics Inc
NASDAQ:CCCCUnited States

Search Criteria

Charts

Recent News

Sep 13, 2024

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024, from 10:00AM ET on Friday Sep 13, 2024 by Dow Jones

Sep 10, 2024

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen, from 7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones

Sep 8, 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024, from 6:05PM ET on Sunday Sep 08, 2024 by Dow Jones

Sep 3, 2024

Press Release: C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors, from 7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors, from 7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar